Elselien Frijlink
Overview
Explore the profile of Elselien Frijlink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frijlink E, Bosma D, Bosma D, Busselaar J, Battaglia T, Staal M, et al.
J Clin Invest
. 2024 Feb;
134(6).
PMID: 38349740
Radiotherapy (RT) is considered immunogenic, but clinical data demonstrating RT-induced T cell priming are scarce. Here, we show in a mouse tumor model representative of human lymphocyte-depleted cancer that RT...
2.
Matas-Rico E, Frijlink E, van der Haar Avila I, Menegakis A, van Zon M, Morris A, et al.
Cell Rep
. 2021 Nov;
37(7):110013.
PMID: 34788605
Autotaxin (ATX; ENPP2) produces lysophosphatidic acid (LPA) that regulates multiple biological functions via cognate G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis via LPAR1 and T cell...
3.
Kierkels G, van Diest E, Hernandez-Lopez P, Scheper W, de Bruin A, Frijlink E, et al.
Mol Ther Methods Clin Dev
. 2021 Sep;
22:388-400.
PMID: 34514030
T cell engineering strategies offer cures to patients and have entered clinical practice with chimeric antibody-based receptors; αβT cell receptor (αβTCR)-based strategies are, however, lagging behind. To allow a more...
4.
Berendsen S, Frijlink E, Kroonen J, Spliet W, Van Hecke W, Seute T, et al.
Neurooncol Adv
. 2020 Jul;
1(1):vdz025.
PMID: 32642660
Background: The antiepileptic drug valproic acid (VPA) inhibits histone deacetylase in glioblastoma cells in vitro, which influences several oncogenic pathways and decreases glioma cell proliferation. The clinical relevance of these...
5.
Kroon P, Frijlink E, Iglesias-Guimarais V, Volkov A, van Buuren M, Schumacher T, et al.
Cancer Immunol Res
. 2019 Feb;
7(4):670-682.
PMID: 30782666
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined, in a poorly immunogenic mouse breast cancer model, the potential of antibody-based immunomodulation...